Literature DB >> 20524958

Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Lisa M Kosloski1, Duy M Ha, Jessica A L Hutter, David K Stone, Michael R Pichler, Ashley D Reynolds, Howard E Gendelman, R Lee Mosley.   

Abstract

Neurodegenerative diseases, notably Alzheimer's and Parkinson's diseases, are amongst the most devastating disorders afflicting the elderly. Currently, no curative treatments or treatments that interdict disease progression exist. Over the past decade, immunization strategies have been proposed to combat disease progression. Such strategies induce humoral immune responses against misfolded protein aggregates to facilitate their clearance. Robust adaptive immunity against misfolded proteins, however, accelerates disease progression, precipitated by induced effector T cell responses that lead to encephalitis and neuronal death. Since then, mechanisms that attenuate such adaptive neurotoxic immune responses have been sought. We propose that shifting the balance between effector and regulatory T cell activity can attenuate neurotoxic inflammatory events. This review summarizes advances in immune regulation to achieve a homeostatic glial response for therapeutic gain. Promising new ways to optimize immunization schemes and measure their clinical efficacy are also discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20524958      PMCID: PMC2923270          DOI: 10.1111/j.1471-4159.2010.06834.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  177 in total

1.  Biochemical and functional characterization of three activated macrophage populations.

Authors:  Justin P Edwards; Xia Zhang; Kenneth A Frauwirth; David M Mosser
Journal:  J Leukoc Biol       Date:  2006-08-11       Impact factor: 4.962

2.  Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.

Authors:  K P Mohanakumar; D Muralikrishnan; B Thomas
Journal:  Brain Res       Date:  2000-05-12       Impact factor: 3.252

3.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

Review 4.  Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Authors:  Joshua J Gagne; Melinda C Power
Journal:  Neurology       Date:  2010-03-23       Impact factor: 9.910

5.  Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages.

Authors:  A Gratchev; J Kzhyshkowska; J Utikal; S Goerdt
Journal:  Scand J Immunol       Date:  2005-01       Impact factor: 3.487

6.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

Review 7.  Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: gastrointestinal-sparing potential drugs.

Authors:  Ratan Singh; Raj Kumar; D P Singh
Journal:  J Med Food       Date:  2009-02       Impact factor: 2.786

8.  Nonsteroidal anti-inflammatory drugs potentiate 1-methyl-4-phenylpyridinium (MPP+)-induced cell death by promoting the intracellular accumulation of MPP+ in PC12 cells.

Authors:  Norimitsu Morioka; Kei Kumagai; Katsuya Morita; Shigeo Kitayama; Toshihiro Dohi
Journal:  J Pharmacol Exp Ther       Date:  2004-05-06       Impact factor: 4.030

9.  A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

Review 10.  The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

Authors:  Howard L Weiner
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

View more
  23 in total

Review 1.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease.

Authors:  Katherine E Olson; Aditya N Bade; Charles R Schutt; Jingdong Dong; Scott J Shandler; Michael D Boska; R Lee Mosley; Howard E Gendelman; Yutong Liu
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

3.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

Review 4.  Activated immune cells in Parkinson's disease.

Authors:  Jun-Jun Cao; Kang-Sheng Li; Yan-Qin Shen
Journal:  J Neuroimmune Pharmacol       Date:  2011-05-10       Impact factor: 4.147

5.  Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.

Authors:  Eun-Jin Bae; He-Jin Lee; Edward Rockenstein; Dong-Hwan Ho; Eun-Bi Park; Na-Young Yang; Paula Desplats; Eliezer Masliah; Seung-Jae Lee
Journal:  J Neurosci       Date:  2012-09-26       Impact factor: 6.167

Review 6.  Prospects of statins in Parkinson disease.

Authors:  Avik Roy; Kalipada Pahan
Journal:  Neuroscientist       Date:  2011-01-20       Impact factor: 7.519

Review 7.  Pathways towards an effective immunotherapy for Parkinson's disease.

Authors:  Jessica A L Hutter-Saunders; Rodney Lee Mosley; Howard E Gendelman
Journal:  Expert Rev Neurother       Date:  2011-12       Impact factor: 4.618

Review 8.  Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells.

Authors:  Hugo González; Francisco Contreras; Rodrigo Pacheco
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-28       Impact factor: 4.147

Review 9.  Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.

Authors:  Mariza Bortolanza; Glauce C Nascimento; Sergio B Socias; Diego Ploper; Rosana N Chehín; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  J Neural Transm (Vienna)       Date:  2018-08-14       Impact factor: 3.575

10.  Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice.

Authors:  Katherine E Olson; Lisa M Kosloski-Bilek; Kristi M Anderson; Breha J Diggs; Barbara E Clark; John M Gledhill; Scott J Shandler; R Lee Mosley; Howard E Gendelman
Journal:  J Neurosci       Date:  2015-12-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.